Post-Transplant Maintenance Acute Leukemia
SNDXSyndax PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Revuforj/Revumenib (SNDX-5613) Post-Transplant Maintenance (Menin Inhibitor) in Post-Transplant Maintenance Acute Leukemia. The expected timing is based on the latest available company guidance and may change.
02/26/26:- Phase 1 revumenib post-transplant maintenance trial in KMT2Ar or NPM1m acute leukemia patients after HSCT is ongoing. 04/30/26:- Post-HSCT maintenance Phase 1 revumenib acute leukemia data from multiple trials and centers expected in Q2 2026. 05/12/26:- Post-HSCT maintenance revumenib data will be presented at EHA 2026 June 13. 05/21/26:- ASCO 2026 oral abstract 6505 post-HSCT maintenance outcomes presented June 2. 06/11/26:- AUGMENT-101 post-HSCT analysis showed 95% 12-month OS and 79% RFS. 08/04/26:- Post-transplant maintenance data expected in H2 2026; MenTain Ph2 around year-end.
Verification
Confirm timing and program details against the company announcement or filing.